Targeting
Cellular
Senescence.
A pioneering biotechnology platform engineered to act on the fundamental mechanisms of tissue aging. By reprogramming cellular pathways, ANIDRACTIV® induces deep molecular regeneration and restores structural integrity.
A new frontier in biotech-based regenerative solutions,
preserving structural integrity and cellular senescence over time.
Piemmeggi is an advanced biotechnology company dedicated to the discovery and development of innovative molecular complexes to counter cellular senescence. The primary focus, driven by the proprietary ANIDRACTIV® platform, is deep tissue regeneration and skin longevity.
Our goal is to reverse the signs of severe skin aging and the loss of viscoelasticity, offering breakthrough solutions for complex structural and inflammatory conditions — including scars, post-acne marks, dermatitis, psoriasis, chronic ulcers and burns.
We believe our highly scientific and disruptive approach will open a new frontier in biotech-based regenerative solutions. Achieving this mission requires extraordinary interdisciplinary effort, secured by robust in-house scientific expertise and an elite network of international partners.
- Tissue reprogrammingReprogramming cellular pathways for deep molecular regeneration.
- Anti-senescenceTargeting the core mechanisms of cellular senescence in skin.
- Scientific rigorFrom in silico computational chemistry to in vivo clinical evidence.
- Structural integrityRestoring tissue viscoelasticity and structural integrity.
A collective of experts in molecular sciences and venture capital.
Founded on Paolo Piazzetta's vision in computational chemistry, Piemmeggi unites molecular scientists and venture builders.
We may succeed or fail, but guided by integrity and respect we do things the right way. We are here to achieve what others deem impossible.
From computational chemistry
to clinical evidence.
The ANIDRACTIV® platform translates rigorous research models — from the in silico level to in vivo — into real and safe solutions for tissue reprogramming and skin longevity.
| Program | Asset | Indication | TRL | Status | Reference |
|---|---|---|---|---|---|
| AND-01 | ANIDRACTIV® — Core Platform | Tissue reprogramming · Skin longevity | TRL9 | EU MD Registration | Completed |
| AND-02 | Severe Skin Aging Program | Loss of viscoelasticity | TRL8 | Real-Life Pre-Market Trial | In vivo evidence — ongoing |
| AND-03 | Scars & Stretch Marks | Scars, stretch marks, post-acne | TRL8 | Pre-Clinical | In silico/vitro/vivo |
| AND-04 | AI driven clinical diagnosis | SaMD | TRL 5 | IN PROGRESS | Model Validation |
Regenerative Medicine Development Pipeline
ANIDRACTIV® is being advanced across selected cutaneous indications with a structured preclinical and regulatory development framework.
| Therapeutic Area | Biological Target | Mechanism of Action | Stage | TRL | Evidence |
|---|---|---|---|---|---|
| Psoriasis | Senescent keratinocyte pathways / IL-17/IL-23 signalling | Modulates senescent cell signalling and reduces cutaneous inflammation. | Preclinical Development | TRL5 | in silico / in vitro |
| Dermatitis | Epidermal barrier integrity / chronic inflammation | Restores barrier function and reduces inflammatory mediators. | Preclinical Development | TRL5 | in silico / in vitro |
| Cutaneous Ulcers | Tissue remodelling / microvascular support | Promotes extracellular matrix reorganisation and angiogenic support. | Discovery Phase | TRL5 | in silico |
| Burns | Re-epithelialisation / fibrotic scarring | Accelerates keratinocyte migration and limits myofibroblast activation. | Discovery Phase | TRL5 | in silico |
An elite network of scientific and industrial partners.
For scientific dialogue, partnership or due diligence.
Reach our R&D, regulatory and business development team. We respond to qualified inquiries within five business days.